文献速递烧伤

烧伤患者妥布霉素药代动力学与每日一次给药的前瞻性研究

A prospective study evaluating tobramycin pharmacokinetics and optimal once daily dosing in burn patients.
PubMed 文献 · Burns · 2017-06-21

在Ross Tilley烧伤中心开展前瞻性单剂量药代动力学试验,纳入TBSA<20%、肌酐清除率≥50mL/min的成人烧伤患者,评估10mg/kg每日一次妥布霉素的达标情况。10例中9例峰浓度≥20mg/L(均值29.4±5.7mg/L),所有患者谷浓度≤0.5mg/L;蒙特卡洛模拟显示10mg/kg达目标峰浓度的概率为97%,约为常规7mg/kg预测值的两倍。结论认为肾功能正常且TBSA<20%的烧伤患者可考虑每日一次给药。

要点

  • 10mg/kg每日一次妥布霉素在TBSA<20%且肾功能正常的烧伤患者中峰浓度达标率高。
  • 妥布霉素半衰期与健康非烧伤患者相似,但表观分布容积较大,支持更高经验剂量。
  • 非肥胖与肥胖患者分别按总体重或调整体重给药,并依据治疗药物监测进一步调整剂量。

核心结论

  • 肾功能正常且TBSA<20%的成人烧伤患者可考虑每日一次妥布霉素给药。
  • 10mg/kg剂量下妥布霉素半衰期与健康非烧伤患者相似,分布容积较大支持较高经验剂量。

研究设计与样本

  • 前瞻性单剂量药代动力学临床试验,在Ross Tilley烧伤中心开展。
  • 纳入TBSA<20%且肌酐清除率≥50mL/min的成人烧伤患者,共10例。
  • 采用一室一级模型,基于每例患者24小时内3或5个妥布霉素浓度点拟合药代动力学参数,并进行蒙特卡洛模拟。

主要发现

  • 平均TBSA、部分厚度及全层烧伤面积分别为10%、6%和4%。
  • 10例中9例峰浓度≥20mg/L(均值29.4±5.7mg/L),所有患者谷浓度≤0.5mg/L。
  • 平均半衰期2.58h、分布容积0.33L/kg、清除率7.40L/h。
  • 蒙特卡洛模拟显示10mg/kg剂量达目标峰浓度的概率为97%,约为常规7mg/kg剂量预测值的两倍。

关键数值与推荐

  • 纳入标准:TBSA<20%且肌酐清除率≥50mL/min的成人烧伤患者。
  • 给药方案:妥布霉素10mg/kg每日一次,非肥胖者按总体重、肥胖者按调整体重计算。
  • 目标峰浓度≥20mg/L,谷浓度≤0.5mg/L;建议依据治疗药物监测进一步调整剂量。

临床怎么用

  • 对TBSA<20%且肾功能正常的烧伤患者,可考虑10mg/kg每日一次妥布霉素经验给药。
  • 非肥胖患者按总体重、肥胖患者按调整体重计算10mg/kg剂量。
  • 给药后应进行治疗药物监测,根据峰谷浓度进一步调整剂量。

局限性

  • 单中心、单剂量、小样本(10例)药代动力学研究。
  • 仅纳入TBSA<20%且肌酐清除率≥50mL/min的患者,结论不能外推至大面积烧伤或肾功能不全者。
  • 未报告临床疗效与毒性结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Once-daily aminoglycoside dosing (ODA) is used in most patient populations to optimize antibacterial activity and reduce toxicity. Unfortunately, burn patients are excluded from ODA due to concerns over altered pharmacokinetics resulting in a shortened half-life and low peak aminoglycoside concentrations. Retrospective studies suggest that ODA may be appropriate if higher milligram/kilogram doses are used. However, no prospective clinical trials in burn patients exist to confirm these findings. OBJECTIVE: To determine the adequacy of once daily tobramycin dosed at 10mg/kg in adult burn patients. METHODS: This prospective single dose pharmacokinetic clinical trial was conducted at the Ross Tilley Burn Centre. Patients with a total burn surface area (TBSA) of <20% and creatinine clearance ≥50mL/min were eligible. A first-order one compartment model was used to determine the pharmacokinetic profile from 3 or 5 tobramycin levels over a 24h period per patient. Monte Carlo simulation (MCS) was performed to determine the probability of target level attainment. RESULTS: The mean percent TBSA, partial, and full thickness burn were 10%, 6%, and 4%, respectively. Nine of the ten patients recruited achieved peak concentrations of ≥20mg/L (mean of 29.4±5.7mg/L) and all patients had a trough level ≤0.5mg/L. The mean half-life, volume of distribution, and clearance were 2.58h, 0.33L/kg, and 7.40L/h, respectively. The MCS determined probability of attaining target peak concentrations with the 10mg/kg dose was 97%, which almost doubled that predicted with the usual 7mg/kg dose. CONCLUSION: Burn patients with adequate renal function and <20% TBSA are candidates for ODA. Tobramycin half-life was similar to healthy, non-burn patients. The larger than normal volume of distribution supports the use of the higher empiric dose of 10mg/kg total body or adjusted weight in non-obese and obese patients, respectively, with further dose adjustment based on therapeutic drug monitoring.

来源:Burns,查看原文。版权归原作者所有。

引用

  1. Lee C, Walker SAN, Walker SE, et al. A prospective study evaluating tobramycin pharmacokinetics and optimal once daily dosing in burn patients. Burns. 2017. PMID: 28647460. doi:10.1016/j.burns.2017.05.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。